Summary
• Pfizer’s stock is up 1.8% to $26.305 during intraday trading, driven by recent collaborative agreements.
• Agreements with Adaptive Biotechnologies focus on T-cell receptor discovery and data licensing for immunology.
• Analysts maintain a “Hold” rating with a cautious outlook, adjusting price targets amid stable quarterly performance.
Pfizer Inc. (PFE) is experiencing a positive price movement, up 1.8% to $26.305 during intraday trading. This marks an increase from the previous close, although specific figures from the last close are not available. The stock’s rise comes amid notable agreements announced in collaboration with Adaptive Biotechnologies.
Collaborative Agreements with Adaptive Biotechnologies
On December 15, 2025, Adaptive Biotechnologies announced two immune receptor licensing agreements with Pfizer. These include a target discovery agreement to identify disease-specific T-cell receptors for rheumatoid arthritis and a data licensing agreement that allows Pfizer to leverage Adaptive’s proprietary TCR-antigen datasets for various immunology applications. This collaboration aims to enhance drug discovery efforts and address autoimmune diseases, potentially opening up new avenues for patient treatment.
Analyst Ratings and Stock Performance Overview
Analyst sentiment reflects a cautious yet stable outlook for Pfizer, categorized as a “Hold” according to recent evaluations. Jason Gerberry from B of A Securities maintained his neutral rating, adjusting the price target slightly from $28 to $29. Concurrently, Terence Flynn of Morgan Stanley upheld an equal-weight rating with a target range of $28 to $32.
Despite recent fluctuations, the stock has shown resilience, with a quarterly performance of 7.8% reflecting some recovery. Over the past 52 weeks, Pfizer has encountered a narrow price range, hitting a low of $23.60 and facing a 52-week high that is around 6.6% lower than its current trading price.
Trading Dynamics and Technical Indicators
Within the trading environment, Pfizer’s average volume over the past 10 days is approximately 44 million shares, while the three-month average volume is about 66 million shares. The stock is currently positioned with a 14-day RSI of 56.3, suggesting that it is in a neutral territory after recent attempts to break into a stronger bullish trend.
On the technical front, the stock shows deviations from its simple moving averages (SMA): 1.66% from the 20-day SMA, 2.8% from the 50-day, and 5.35% from the 200-day SMA. These indicators highlight a balanced trading approach, with volatility averages holding at around 2.3% on both weekly and monthly assessments.
Outlook
As Pfizer navigates its collaborations and regulatory landscape, feedback from analysts and positive price movements underscore a cautious optimism regarding its strategic direction. Investors will likely keep a close watch on upcoming financial guidance discussions set for December 16, which may further clarify the company’s trajectory moving forward.